3-V Biosciences has changed its name to Sagimet Biosciences after closing a series E round backed by strategic partner Ascletis at $25m.

Sagimet Biosciences, a US-based developer of treatments for fatty acid synthase, increased its series E round to $25m on Monday following an extension led by hepatitis C drug developer Ascletis Pharma. Qianhai Ark Investment, New Enterprise Associates (NEA) and Kleiner Perkins also took part in the extension, all four investors having contributed to the round’s…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.